Lion Point Capital LP Sells 15,500 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Lion Point Capital LP decreased its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 25.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,900 shares of the company's stock after selling 15,500 shares during the period. Kiniksa Pharmaceuticals accounts for 4.8% of Lion Point Capital LP's investment portfolio, making the stock its 8th biggest position. Lion Point Capital LP owned approximately 0.06% of Kiniksa Pharmaceuticals worth $908,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in KNSA. Franklin Resources Inc. grew its position in shares of Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock valued at $1,798,000 after purchasing an additional 1,100 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at $4,997,000. Hennion & Walsh Asset Management Inc. grew its position in shares of Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company's stock valued at $3,947,000 after purchasing an additional 3,673 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at $355,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after purchasing an additional 1,004 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Analyst Ratings Changes

KNSA has been the subject of a number of recent analyst reports. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $38.80.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the transaction, the chief accounting officer now owns 26,528 shares in the company, valued at $595,553.60. The trade was a 25.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ross Moat sold 6,272 shares of the business's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $28.00, for a total value of $175,616.00. Following the transaction, the insider now owns 9,415 shares in the company, valued at approximately $263,620. This represents a 39.98% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 228,768 shares of company stock worth $5,591,506 over the last quarter. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA traded down $0.57 during trading on Wednesday, reaching $25.03. 555,515 shares of the stock were exchanged, compared to its average volume of 482,831. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $17.38 and a 12-month high of $28.56. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -178.77 and a beta of 0.07. The firm's 50-day moving average price is $22.67 and its 200 day moving average price is $21.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company's revenue for the quarter was up 72.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.25) EPS. As a group, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.